Inhaled steroid/long-acting β2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients

Respiratory Research

Volumn 7, Issue , 2006, Pages

  Lötvall, Jan ^a   Langley, Stephen ^b   Woodcock, Ashley ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; ANDROSTANE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ADRENERGIC, BETA-2;

EID: 33748878748     PISSN: 1465993X     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-7-110     Document Type: Article

References (28)

1. Greening AP, Ind PW, Northfield M, Shaw G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited study group. Lancet 1994, 344:219-24.
2. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K: The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol 1999, 82:383-9.
3. Pauwels TA, Lofdahl C-G, Postma DS, Pride NB, Ohlsson SV: Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997, 337:1405-11.
4. Aubier M, Pieters W, Schlosser N, Steinmetz KO: Salmeterol/fluticasone propionate (50/500 mcg) in combination on a DISKUS inhaler (SERETIDE) is effective and safe in the treatment of steroid dependent asthma. Respir Med 1999, 93:876-84.
5. Kavuru M, Melamed J, Gross G, LaForce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T: Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomised, double blind placebo controlled trial. J Allergy Clin Immunol 2000, 105:1108-16.
6. Van den Berg NJ, Ossip M, Hederos CA, Antilla H, Ribeiro BL, Davies PI: Salmeterol/fluticasone propionate (50/100 mcg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Paed Pulmonol 2000, 30:97-105.
7. Zetterström O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S, Ekstrom T: Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001, 18:262-8.
8. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, De Boeck K: Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002, 34:342-50.
9. Palmqvist M, Arvidsson P, Beckman O, Petersen S, Lotvall J: Onset of bronchodilatiation of budesonide/formoterol vs salmeterol/fluticasone in single inhalers. Pulm Pharmacol The 2001, 14:29-35.
10. Van der Woude HJ, Boorsma M, Bergqvist PB, Winter TH, Aalbers R: Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004, 17:89-95.
11. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FP: Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996, 9:1684-8.
12. Ringdal N, Derom E, Wahlin-Boll E, Pauwels R: Onset and duration of action of single doses of formoterol inhaled via BADPI. Respir Med 1998, 92:1017-21.
13. Kemp JP, Bierman CW, Cocchetto DM: Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann Allergy 1993, 70:316-22.
14. Buhl R, Creemers JP, Vondra V, Martelli NMA, Nava IP, Ekstrom T: Once daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 2003, 97:323-30.
15. Goryachkina L, Boonsawat W, Millns H, Balsara S: Seretide/AdvairTM 50/ 100 mcg once daily is effective in patients with mild asthma. Am J Respir Crit Care Med 2004, 169(7):A86.
16. Johnson M: Salmeterol. Med Res Rev 1995, 15:225-7.
17. Nials AT, Coleman RA, Johnson M, Magnussen H, Rabe KF, Vardey CJ: Effects of β-adrenoceptor agonists in human bronchial smooth muscle. Br J Pharmacol 1993, 110:1112-6.
18. Bootsma GP, Dekhuijen PNR, Fesetn J, Lammers JW, Mulder PG, van Herwaarden CL: Sustained protection against distilled water provocation by a single dose of salmeterol in patients with asthma. Eur Respir J 1997, 10:2230-6.
19. Faurschou P, Engel AM, Haannaes OC: Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 1994, 49:827-32.
20. Maesen FPV, Smeets JJ, Gubbelmans HLL, Zweers PG: Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest 1990, 97:590-4.
21. Arvidsson P, Larsson D, Lofdahl CG: Objective and subjective bronchodilation over 12 hours after inhaled formoterol: individual responses. J Asthma 1993, 30:459-63.
22. Sykes AP, Ayres JG: A study of the duration of the bronchodilator effect of 12 mcg and 24 mcg of inhaled formoterol and 200 mcg inhaled salbutamol in asthma. Respir Med 1990, 84:135-8.
23. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T: Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatr Allergy Immunol 2004, 15:32-9.
24. Palmqvist M, Persson L, Lazer J, Rosenborg J, Larsson P, Lotvall: Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997, 10:2484-9.
25. Rabe KF, Jorres R, Nowak D, Behr N, Magnussen H: Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993, 147:1436-41.
26. Verberne AA, Fuller R: An overview of nine clinical trials of salmeterol in an asthmatic population. Respir Med 1998, 92:777-82.
27. Pearlman D, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW: A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med 1992, 327:1402-5.
28. Ringdal N, Chuchalin A, Chovan L, Tudoric N, Maggi E, Whitehead PJ: Evaluation of different inhaled combination therapies (EDICT): a randomised, double blind comparison of Seretide (50-250 mcg bd Diskus vs. formoterol (12 mcg bd) and budesonide (800 mcg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. Respir Med 2002, 96:851-61.